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Intravenous immunoglobulin (IVIG) products are prepared from purified plasma immunoglobulins from large
numbers of healthy donors. Pilot studies with the IVIG preparations Octagam and Gammagard in individuals with
mild-to-moderate Alzheimer’s disease (AD) suggested stabilization of cognitive functioning in these patients, and a
phase II trial with Gammagard reported similar findings. However, subsequent reports from Octagam’s phase II trial
and Gammagard’s phase III trial found no evidence for slowing of AD progression. Although these recent
disappointing results have reduced enthusiasm for IVIG as a possible treatment for AD, it is premature to draw final
conclusions; a phase III AD trial with the IVIG product Flebogamma is still in progress. IVIG was the first attempt to
use multiple antibodies to treat AD. This approach should be preferable to administration of single monoclonal
antibodies in view of the multiple processes that are thought to contribute to AD neuropathology. Development of
“AD-specific” preparations with higher concentrations of selected human antibodies and perhaps modified in other
ways (such as increasing their anti-inflammatory effects and/or ability to cross the blood–brain barrier) should be
considered. Such preparations, if generated with recombinant technology, could overcome the problems of high
cost and limited supplies, which have been major concerns relating to the possible widespread use of IVIG in AD
patients. This review summarizes the recent AD IVIG trials and discusses the major issues relating to possible use of
IVIG for treating AD, as well as the critical questions which remain.
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Introduction
The severity of the Alzheimer’s disease (AD) problem in
the US is indicated by recent statistics from the
Alzheimer’s Association [1]. Approximately 5.4 million
Americans are currently diagnosed with AD, including
one in eight individuals aged 65 and older. By 2025 the
number of Americans aged 65 and older with AD is
expected to reach 6.7 million. Payments for health care,
long-term care, and hospice for AD patients, which are
currently estimated at $200 billion, are expected to be
$1.1 trillion (in 2012 dollars) by 2050.
Intravenous immunoglobulin (IVIG) products are being
investigated as potential agents for treatment or preven-
tion of AD. IVIG is prepared from plasma immunoglobu-
lins from large numbers (>10,000) of healthy donors. It is
used to treat a range of autoimmune, infectious, and
idiopathic disorders [2]. The IVIG product Octagam
(Octapharma) was shown by Dodel et al. in 2002 to con-
tain antibodies to Aβ, suggesting that IVIG might be use-
ful for treatment of AD [3]. This provided the rationale
for IVIG pilot studies in AD patients. The results of these
studies were encouraging [4,5], leading to phase II AD tri-
als with these products. Positive results were reported for
one of the two IVIG products [6,7] but not the other one
[8]. More recently, negative results were reported in a
phase III IVIG study [9]. An additional phase III AD trial
with another IVIG product is in progress.
As of this writing (May 2013) it is unclear whether any
IVIG products will offer a breakthrough for treatment of
AD. Because these preparations differ in their concentra-
tions of antibodies to Aβ [10-12] and tau protein [13],
there may be differences between them with regard to
their efficacies in AD. This purpose of this review is to
summarize the IVIG AD trials conducted to date, the
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issues raised by the potential use of IVIG for treatment of
AD, and critical questions which remain.
Clinical trials with IVIG in AD patients
IVIG treatment of AD patients was first reported in a pilot
study in 2004 [4]. Five patients with mild to moderate AD
[Mini Mental State Examination (MMSE) mean score
19.4] received Octagam (Octapharma; dose = 0.4 g/kg) on
3 successive days, every 4 weeks for 6 months. MMSE
scores improved slightly in four of the AD patients and
were unchanged in the fifth one, while their Alzheimer's
Disease Assessment Scale-Cognitive sub-scale (ADAS-cog)
scores decreased, suggesting increased cognitive function-
ing, in four patients and did not change in the fifth one. In
2009 results were published [5] from a pilot study in which
eight AD patients (mean MMSE score 23.5) were admi-
nistered Gammagard S/D (Baxter Healthcare). After 6
months of treatment the mean MMSE score increased to
26.0, reflecting increased scores for six patients and no
change in scores for two patients. After a 3-month washout
period, the mean MMSE score returned to baseline (23.9).
Following an additional 9 months of treatment, MMSE
scores were essentially unchanged (mean 24.0).
Before publishing these results, in 2006 Baxter began a
double-blind Phase II AD trial with Gammagard. Im-
proved outcomes were noted in the Gammagard-treated
subjects compared to those initially treated with placebo
at 3, 6, and 9 months [6]. The four patients who received
Gammagard at 0.4 g/kg every 2 weeks for 36 months
showed no evidence of further cognitive or memory de-
cline [7].
The results of a double-blind, placebo-controlled, 24-
week phase II AD trial with Octagam were published in
January 2013 [8]. Octagam had no apparent effects on cog-
nitive or functional scores in the AD patients. No increase
was found for plasma Aβ1-40; this had been reported in
the pilot studies and suggested that IVIG products might
increase efflux of Aβ from the brain. The only positive
finding reported in this study, less reduction in glucose
metabolism in some brain regions in the Octagam-treated
individuals, was of uncertain significance.
In May 2013, the results of a placebo-controlled phase
III AD trial with Gammagard were announced [9]. Three
hundred ninety patients had been treated every 2 weeks
for 18 months with 200 mg/kg Gammagard, 400 mg/kg
Gammagard, or placebo. No significant differences were
found for the rate of cognitive decline between the
Gammagard-treated group and placebo group.
Two AD-related IVIG trials are still in progress.
Flebogamma (Grifols Biologicals) is being evaluated, to-
gether with albumin, in an AD phase III trial, and
NewGam (Octapharma) is being investigated by Sutter
Health in a phase II trial to determine its effects in pa-
tients with amnestic mild cognitive impairment (MCI)
and its influence on the risk for these patients to develop
AD. A possible reason for the failures in the most recent
IVIG trials is that by the time AD’s clinical features be-
come evident, its pathology, including extensive neuronal
loss, is already wellestablished. The trial with MCI patients
should provide an indication of whether earlier IVIG
treatment may be beneficial. The findings of a retrospect-
ive study [14], that individuals 65 years of age and older
who had received IVIG had a significantly reduced risk for
developing AD and related disorders compared to subjects
not receiving IVIG support this possibility.
Considerations relating to treatment of AD with
IVIG products
Economic considerations
Approximately 22 million plasma donations were col-
lected in the US in 2009. Processing of a plasma sample
into IVIG requires about 9 months. The use of IVIG for
treatment of AD could pose a threat to its supplies. Solu-
tions that have been suggested to this problem include
new manufacturing processes, use of recombinant tech-
nology to produce IVIG, or administration of specific anti-
bodies in place of IVIG [15]. Because of problems with
obtaining adequate amounts of IVIG, some hospitals re-
quire consideration of alternatives to IVIG for treatment
of patients with neurological disorders [16].
IVIG treatment is expensive, although its actual cost
varies with the dose, frequency of administration, and
home vs. hospital infusion. The Medicare Modernization
Act of 2003 fixed Medicare’s IVIG reimbursement rate to
doctors and hospitals at the average sale price for IVIG
plus 6%. Although the federal “340B drug discount” pro-
gram mandates discounted IVIG prices for hospitals that
provide high volumes of care to low-income patients [17],
some hospitals have been unable to buy IVIG at these
prices [18].
Potential side effects of IVIG
Thromboembolic events
IVIG can lead to thromboemboli because it increases
serum viscosity, resulting in reduced blood flow [19]. Pre-
existing vascular disease and immobility, additional factors
that increase the risk for thromboembolic events [20], are
often present in elderly individuals, including those with
AD [21,22]. In patients with neuropathies that received
IVIG, immobility was found to be an independent pre-
dictor for the development of thromboemboli [23]. Vascu-
lar disease and immobility in AD patients could therefore
increase the risk of these individuals for IVIG-induced
thromboembolic events.
Renal problems
Renal dysfunction, acute renal failure, and osmotic neph-
rosis can result from IVIG treatment in patients with
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predisposing conditions such as renal insufficiency, dia-
betes mellitus, age > 65, volume depletion, sepsis, or re-
ceiving nephrotoxic drugs [24,25]. This is particularly true
for IVIG products that use sucrose as a stabilizing agent.
The prevalence of chronic renal disease increases with
age, peaking at nearly 24% at ages 70–74 [26], so elderly
individuals are likely to have an increased risk for IVIG-
induced kidney problems because of pre-existing renal
disease. AD patients with impaired kidney function may
therefore not be candidates for IVIG treatment.
Hematological deficits
Decreases in WBCs, RBCs, and platelets have been
reported after IVIG treatment [27-30]. The mechanisms
responsible for these alterations are unclear. IVIG can
stimulate platelet aggregation [31], which could reduce
platelet counts. Binding of high-molecular-weight IgG
complexes in IVIG to RBCs could decrease hematocrit
levels in IVIG-treated patients by increasing RBC seques-
tration [32]. Binding of neutrophils to the vascular wall
and migration of these cells into a storage pool has been
suggested as a mechanism for IVIG-induced neutropenia
[33]. Similar to the situation with regard to renal prob-
lems, individuals with AD who have hematological abnor-
malities may not be able to receive IVIG.
Potential mechanisms of action of IVIG in AD
IVIG products are thought to contain the full range of
antibodies present in the human repertoire, estimated at
109 [15]. IVIG’s mechanisms of action in different disor-
ders are generally poorly understood. It contains several
antibodies that have the potential to reduce AD-type
pathology, but whether these antibodies can actually do
so is unclear.
Anti-Aβ effects
IVIG products contain antibodies to Aβ oligomers and fi-
brils [34] and perhaps also to monomeric Aβ [11,35].
These drugs differ in their levels of anti-Aβ antibodies
[10-12]. IVIG has been shown in vitro to disaggregate
preformed Aβ fibrils, promote Aβ phagocytic removal
[36], protect against Aβ neurotoxicity [35,37], and prevent
formation of Aβ soluble oligomers [11]. But studies in
mouse models of AD have produced conflicting results as
to whether IVIG products can reduce brain Aβ. Magga
et al. [38] found that Gammagard promoted microglial-
mediated clearance of Aβ in experiments with brain sec-
tions from APP/PS1 mice and reduced in vitro Aβ fibril
formation, but the latter effect was not specific for its
anti-Aβ antibodies. Dodel et al. [37] treated APP695
double mutant mice with purified anti-Aβ antibodies from
Octagam for 4 weeks beginning at 3 or 12 months of age.
Reduced plaque counts were found in the younger mice
but not in the older mice. Puli et al. [39] treated TgApdE9
mice with Gammagard beginning at 4 months of age, for
3 or 8 months. In the 3-month-treated group, there were
no effects on hippocampal plaque counts or brain Aβ.
After 8 months, there were still no differences in plaque
counts between treatment and control groups. Surpris-
ingly, soluble Aβ levels in hippocampus were increased in
treated mice.
IVIG’s antibodies recognize multiple sites on conform-
ational Aβ epitopes, and its main binding to Aβ is report-
edly to Aβ25-40 [12,37]. This differs from the monoclonal
anti-Aβ antibodies that have been used in clinical trials,
Bapineuzumab and Solanezumab, which recognize only
one epitope in linear Aβ and bind to Aβ1-5 and Aβ13-28,
respectively [40]. A recent review [41] suggested that
using the IVIG polyclonal antibody approach in an effort
to deplete the spectrum of aggregated Aβ species might
be more promising than using monoclonal antibodies
targeting a single Aβ species.
Anti-inflammatory effects
IVIG can inhibit complement activation [42], neutralize
inflammatory cytokines [43], and modulate chemokine ex-
pression [44] and regulatory T cell subsets [45]. However,
its main anti-inflammatory effects are thought to be due
to its IgG Fc fragments [46,47]. IVIG may not have re-
duced brain inflammation in the AD clinical trials because
high doses (1–2 g/kg) are required for it to exert these
effects [48]. Ravetch and colleagues investigated the
mechanism by which IVIG’s Fc fragment produces anti-
inflammatory effects. The constant domain of IgG’s Fc
contains a glycan (a core heptapolysaccharide containing
N-acetylglucosamine and mannose at Asn297) [49]. In
serum antibodies, this includes a terminal sialic acid,
which is responsible for Fc’s anti-inflammatory effects
[50]. This form of the carbohydrate is present in only 1-3%
of IVIG’s IgG molecules, which may explain why high-
dose IVIG is required to produce anti-inflammatory ef-
fects [51].
Possible anti-tau effects
Cognitive deficits in AD strongly correlate with neurofibril-
lary tangle (NFT) density and distribution [52,53]. Aggre-
gation and hyperphosphorylation of tau are required to
produce NFTs. Studies in transgenic mouse models of
tauopathy found that administration of antibodies to phos-
phorylated tau reduced tau pathology [54,55], so if IVIG
contains such antibodies, they might be beneficial for
treatment of AD. We recently reported the presence of
antibodies to recombinant human tau, which is un-
phosphorylated, in IVIG products [13]. The significance of
these antibodies to “normal” tau (i.e., whether these anti-
bodies can reduce tau oligomer formation or inhibit its
neurotoxicity) and whether IVIG also contains antibodies
to aggregated and hyperphosphorylated tau are unknown.
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Alteration of Aβ passage in and out of the brain
Advanced glycation endproducts (AGEs) form when redu-
cing sugars react with amino groups in proteins, lipids,
and nucleic acids [56]. The receptor for AGEs (RAGE) is
present on the blood–brain barrier (BBB) [57], where it
transports Aβ into the brain [58]. Anti-RAGE antibodies
have been reported in IVIG [59]. These antibodies could
reduce Aβ influx into the brain.
Low-density lipoprotein receptor-related protein-1
(LRP1) is the main receptor for transporting Aβ out of
the brain [60]. LRP-1 expression on the BBB is reduced
in AD [61]. Soluble LRP (sLRP) has also been reported in
IVIG [59]. sLRP binds 70–90% of plasma Aβ, preventing
it from entering the brain [62], so increasing peripheral
blood sLRP levels through IVIG treatment might help to
lower brain Aβ levels.
Non-antibody-mediated effects
IVIG contains other non-antibody proteins in addition
to sLRP, which could influence its actions in AD in ways
that are not clear. Interferon-γ, an inflammatory cyto-
kine that also has some anti-inflammatory actions [63],
is present in IVIG [64]. Soluble human leukocyte antigen
(HLA) class I and II molecules are present in some IVIG
products, as are their “physiological ligands,” CD4 and
CD8 [65,66]. Soluble CD4 in IVIG might interfere with
HLA class II molecules on antigen-presenting cells,
competing with HLA-class II-restricted T cells and pos-
sibly causing immunosuppression [66,67]. Transforming
growth factor (TGF)-β1 and TGF-β2 are also present in
IVIG [68].
TGF-β1 is increased in AD brain, where it is associated
with plaques [69], but it also may promote Aβ clearance
[70], so its significance in AD is unclear.
Might IVIG products differ with respect to their effects
in AD?
Differences have been reported between IVIG products
for the concentrations of some of their antibodies and
their biological activities [71-75]. These may be due to dif-
ferences in manufacturing practices and/or the antigenic
exposure of the plasma donors. With regard to AD, differ-
ences between IVIG preparations have been found for
anti-Aβ [10-12] and anti-tau antibodies [13], as mentioned
earlier. Determination of whether IVIG products differ in
their ability to slow AD’s progression will require com-
parative studies, as have been done for Kawasaki disease
[76] and primary immune deficiency [77].
How might the IVIG approach to AD treatment
be improved?
Production of an “AD-specific” human immunoglobulin
preparation would allow selected antibodies to be admin-
istered in higher concentrations than is possible with
unfractionated IVIG. There are precedents for this. Poly-
clonal anti-D, a type of IVIG consisting of plasma from
RhD-negative donors immunized to the D antigen [78],
has been used to treat idiopathic thrombocytopenic pur-
pura [79,80], and Shoenfeld and colleagues [81] have gen-
erated specific IVIG (sIVIG) preparations for a number of
immune-mediated conditions including lupus and anti-
phospholipid syndrome. These antibodies could be pro-
duced with recombinant technology to avoid potential
supply difficulties. A second possibility could be to admin-
ister multiple “humanized” mouse monoclonal antibodies
with antigenic specificities similar to those of the anti-
bodies in the AD-specific human IgG preparations. Single
chain antibody fragments, which have been suggested as
alternatives to monoclonal antibodies for AD treatment
[82], should have better BBB penetration than intact IgG
molecules. Still another alternative could be administration
of recombinant sialylated Fc fragments, as suggested by
Bayry et al. [15] for autoimmune diseases; as discussed
above, this modification increases Fc’s anti-inflammatory
properties [49,50]. Sialic acid-enriched immunoglobulins
have been obtained from IVIG by lectin fractionation
[49,83].
Critical questions remaining
The most important question relating to AD treatment
with IVIG is clearly whether any IVIG products will con-
sistently slow clinical progression of this disorder. Ques-
tions that, if addressed, could lead to improved efficacy
for IVIG in the treatment of AD include the following:
1. Regarding the antibodies in IVIG that have been
identified against AD pathological proteins: what are
their effects in mouse transgenic models of AD that
develop both plaques and NFTs? (Although the
complement membrane attack complex, C5b-9, is
present on plaques and neurofibrillary tangles in the
AD brain [84,85], the currently available mouse
transgenic models of AD do not demonstrate this
late-stage complement activation [86], so the effects
of IVIG’s anti-complement antibodies on this process
cannot presently be studied in animal models of AD.)
2. What other AD-related antibodies are present in
IVIG? (Does IVIG have antibodies against
aggregated or hyperphosphorylated tau or antibodies
that have antioxidant effects? Do its anti-Fas
antibodies [72] have any relevance for AD
treatment?)
3. Do IVIG’s anti-idiotypic antibodies influence its
effects in AD? These antibodies are thought to be
responsible for IVIG’s benefits in autoimmune
disorders [87], but their effects in AD are unknown.
4. Are IVIG’s effects in AD similar between apoE4
carriers and non-carriers? (In the phase III
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Gammagard trial [9], it was suggested that the 400
mg/kg dose may have been of some benefit to
apoE4+ AD patients).
5. Does IVIG treatment of AD patients increase their
risk for microhemorrhage? (In the phase II Octagam
study, 14% of the Octagam-treated patients had
microhemorrhages vs. none in the placebo group [8]).
Conclusions
The IVIG trials reported to date in AD patients have
produced conflicting findings. Because the most recent
trials produced negative results, enthusiasm for IVIG as
a treatment for AD has been reduced, although hope re-
mains that the phase III trial with Flebogamma will pro-
duce positive results. Multiple antibody therapy for AD,
as typified by IVIG, should have advantages over admin-
istration of individual monoclonal antibodies. To identify
which antibodies should be included in an AD-specific
IVIG preparation, more must be known about the range
of anti-AD antibodies in IVIG and their effects on AD
pathology in animal models. Such an AD-specific IVIG
preparation, modified to increase the concentration,
anti-inflammatory activity, and perhaps the brain pene-
tration of its antibodies, might be more beneficial to AD
patients than treatment with unfractionated IVIG.
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